Acute ischemic stroke secondary to large-vessel occlusion represents one of the most critical neurological emergencies worldwide. Rapid reperfusion therapies directly determine functional recovery and patient independence. In decentralized healthcare systems, many individuals present first to primary stroke centers lacking on-site neurointerventional suites. Consequently, physicians must arrange urgent transfer to comprehensive stroke centers for mechanical intervention. Within this framework, clinicians often debate the utility and safety of initiating pharmacological reperfusion before transport. Recent high-level evidence firmly clarifies this dilemma. Implementing pre-transfer intravenous thrombolysis significantly enhances vascular reopening and survival while patients travel between medical facilities.

Clinical Rationale for Pre-Transfer Intravenous Thrombolysis

Time remains the most decisive determinant of tissue survival in ischemic cerebral insults. When large-vessel occlusions occur, millions of neurons die each minute without adequate collateral blood flow. Therefore, initiating thrombolytic therapy at the primary center establishes early chemical reperfusion during ambulance transit. This operational strategy, widely termed the drip-and-ship paradigm, utilizes the transit interval constructively. Opponents historically raised concerns that chemical thrombolysis might cause symptomatic intracranial hemorrhage or delay interfacility departure. Furthermore, critics argued that systemic thrombolytic drugs rarely achieve complete recanalization in proximal occlusions. However, accumulating clinical data strongly dispute these traditional reservations. Early administration of systemic thrombolytic drugs destabilizes fresh thrombi and facilitates microvascular perfusion downstream from the primary occlusion. Consequently, salvageable brain tissue receives critical oxygenation before the mechanical thrombectomy catheter even engages the clot. Moreover, early enzymatic action softens the fibrin architecture of stubborn clots. This structural softening subsequently improves the speed and success rate of mechanical clot retrieval at the receiving comprehensive center. Because transport times across regional networks can exceed sixty to ninety minutes, early pharmacological initiation transforms passive transport time into an active, protective therapeutic window.

Key Efficacy Outcomes and Arterial Recanalization Rates

A comprehensive systematic review and meta-analysis published in the Journal of Neurology synthesized evidence from sixteen observational cohorts to evaluate patient outcomes. The investigators compared acute ischemic stroke patients receiving bridging systemic thrombolysis against those undergoing transfer without pre-treatment. Most impressively, patients receiving systemic therapy achieved dramatic improvements in 90-day clinical recovery. The pooled analysis revealed that pre-transfer treatment substantially increased the odds of achieving an excellent functional outcome, defined as a modified Rankin Scale score of zero to one. Specifically, patients who received pre-transfer thrombolytic therapy demonstrated a 72% higher likelihood of full functional independence compared to non-thrombolyzed peers. Similarly, good functional outcomes, defined as modified Rankin Scale scores of zero to two, increased significantly by 64%. Most strikingly, the odds of complete interhospital arterial recanalization surged more than sevenfold in the treated group. In numerous cases, the occluded cerebral artery opened entirely before the patient reached the catheterization laboratory. Consequently, neurointerventionalists could avoid invasive mechanical instrumentation altogether in these specific individuals. Furthermore, systemic treatment reduced poor functional outcomes and cut 90-day all-cause mortality by 31%. These statistical findings robustly validate pharmacological bridging as a life-preserving intervention.

Safety Profile and Intracranial Hemorrhage Considerations

Safety considerations have historically made emergency physicians hesitant to administer clot-busting medications immediately before high-speed interfacility transfers. Specifically, clinicians feared that blood pressure surges during ambulance transport might precipitate devastating parenchymal hematomas. In addition, medical teams worried about managing acute neurological deterioration in an enclosed transit vehicle without immediate neurosurgical back-up. Nevertheless, rigorous safety analyses from the pooled literature offer profound reassurance for clinical practitioners. The systematic review confirmed that pre-transfer thrombolysis did not produce statistically significant increases in symptomatic intracranial hemorrhage compared to direct thrombectomy transfers. Although rates of minor, asymptomatic petechial hemorrhages showed modest variations across individual registries, severe hemorrhagic transformation and large parenchymal hematomas remained remarkably equivalent between groups. Furthermore, the substantial reduction in 90-day mortality directly refutes the assumption that systemic lytic agents cause unacceptable hemorrhagic harm. Careful patient selection and stringent exclusion of coagulopathies ensure maximum therapeutic safety. In addition, maintaining strict systolic blood pressure control below 180 millimeters of mercury during ambulance transport further minimizes intracranial bleeding complications. Thus, available scientific evidence indicates that withholding systemic thrombolysis out of bleeding fears ultimately deprives eligible stroke patients of substantial clinical benefits.

Operational Logistics in the Drip-and-Ship Paradigm

Achieving excellent clinical outcomes requires seamless operational coordination between referring community facilities and comprehensive receiving centers. Emergency medical teams must never allow the administrative or technical process of drug reconstitution to delay transport vehicle dispatch. In practical acute workflows, nursing staff can initiate intravenous alteplase infusions while emergency personnel prepare the patient for immediate transfer. Alternatively, single-bolus tenecteplase provides distinct operational advantages over traditional alteplase infusions. Because clinicians administer tenecteplase as an instantaneous five-second intravenous push, it eliminates the need for maintaining complex intravenous infusion pumps inside moving ambulances. As a result, referral facilities can dispatch ambulances immediately without fear of pump malfunction or infusion line displacement. Moreover, recent randomized trials confirm that tenecteplase achieves superior early recanalization rates compared to alteplase in large-vessel occlusions. Therefore, emergency departments should update their acute protocols to incorporate tenecteplase whenever national formularies permit. Simultaneously, primary stroke centers must transmit diagnostic neuroimaging data electronically to the neurointerventional team during transport. This parallel communication allows the comprehensive team to prepare the angiography suite well before the patient arrives, eliminating avoidable delays.

Translating Evidence to Acute Stroke Systems of Care

The implications of these pooled findings extend directly to healthcare policy, regional emergency networks, and resource allocation. In developing and geographically diverse regions, specialized endovascular thrombectomy facilities concentrate primarily in major urban academic medical centers. Consequently, the vast majority of stroke patients must travel significant distances to reach mechanical intervention. Restricting acute reperfusion exclusively to tertiary catheterization suites would deny millions of individuals prompt arterial recanalization. Therefore, health systems must empower primary stroke centers through standardized protocols, tele-stroke guidance, and rapid-access thrombolytic supplies. When emergency physicians recognize eligible candidates within the standard four-and-a-half-hour treatment window, they should initiate pharmacological thrombolysis immediately. Furthermore, health authorities must establish rapid interfacility transport agreements to streamline transfer logistics. Routine training for paramedic personnel in airway management and neurological monitoring during transit further reinforces safety. Clinicians at comprehensive centers must also repeat vascular imaging upon patient arrival, because spontaneous recanalization occurs in approximately ten to fifteen percent of thrombolyzed patients. Recognizing early vascular reopening spares patients unnecessary catheterization and optimizes critical hospital resources. Ultimately, collaborative regional protocols bridge therapeutic inequities and maximize functional independence across diverse patient populations.

Does pre-transfer thrombolysis increase symptomatic intracranial hemorrhage?

Current clinical evidence indicates that pre-transfer thrombolysis does not significantly increase symptomatic intracranial hemorrhage in large-vessel occlusion stroke. Although systemic thrombolytics elevate minor asymptomatic bleeding risk slightly, severe parenchymal hematoma rates remain comparable. Stringent blood pressure control below 180 mmHg and proper patient screening maintain a favorable safety profile during interhospital transit.

Why is tenecteplase increasingly preferred over alteplase for transfer patients?

Tenecteplase offers practical advantages because clinicians administer it as a rapid single intravenous bolus. This eliminates the need for maintaining precision infusion pumps during emergency ambulance transfers. Additionally, tenecteplase possesses higher fibrin specificity and a longer half-life, which promotes higher early recanalization rates before patients reach comprehensive stroke centers for thrombectomy.

Should ambulance dispatch wait until the full alteplase infusion completes?

Clinicians must never delay ambulance transfer to finish a sixty-minute alteplase infusion. Emergency protocols recommend initiating the intravenous bolus and starting the maintenance infusion, then dispatching the transport vehicle immediately. Dedicated transport teams monitor the infusion pump en route. Avoiding interfacility transport delays remains essential to protect salvageable ischemic brain tissue.

Disclaimer: This content is for informational and educational purposes only, and does not constitute medical advice or establish a doctor-patient relationship. Healthcare professionals should independently verify all clinical information and exercise their professional judgment. Readers should consult original research and guidelines. Refer to the latest local and national guidelines for clinical practice.

References

1. Wang Z et al. Intravenous thrombolysis use before interhospital transfer for thrombectomy: a systematic review and meta-analysis. J Neurol. 2026 Sep 28. doi: 10.1007/s00415-026-14173-6. PMID: 42803981.
2. Seners P et al. Arterial Recanalization During Interhospital Transfer for Thrombectomy. Stroke. 2024;55(7):1812-1821. doi: 10.1161/STROKEAHA.124.046985.
3. Goyal M et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387(10029):1723-1731. doi: 10.1016/S0140-6736(16)00163-X.
4. Powers WJ et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update. Stroke. 2019;50(12):e344-e418. doi: 10.1161/STR.0000000000000211.